• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Compounds of formula wherein R,, R2 and R3 are each independently selected from H, OH, C1-C4alkyl, R4-CO and halogen, where R. is C1-C4alkyl; R5 and R. are each independently selected from H, C1-C4alkyl and optionally-substituted phenyl; R7 is an alkylene group having from 1 to 4 carbon atoms, optionally containing a substituted or unsubstituted phenyl group; p or 0 or 1; and Z is a 1H-tetrazol-5-yl or a -CN group; and salts thereof, may be prepared by reacting a compound of formula. with a compound of formula wherein R1-R7 are as defined in claim 1, in an organic solvent at a temperature in the range of 40-120°C in the presence of a base, and reacting the resulting compound with an alkali metal cyanide orthiocyanate, and optionally reacting the resulting compound with a source of azide ions to produce pharmacologically active compounds of formula I wherein Z is 1H-tetrazol-5-yl.
    公开号:SU1340585A3
    申请号:SU843770848
    申请日:1984-07-11
    公开日:1987-09-23
    发明作者:Джеймс Стегглс Дэвид；Помфрет Вердж Джон
    申请人:Лилли Индастриз Лимитед (Фирма)；
    IPC主号:
    专利说明:

    11340585
    This invention relates to a process for the preparation of tetrazole derivatives not described in the literature.
    te va ro
    )
    where, OH, C, -C-alkyl;
    where R4 is C-alkyl; R is C-C-alkyl;
    P 0.1
    possessing physiological activity, in particular being leukotriene antagonists.
    The purpose of the invention is to develop a method for producing new tetrazole derivatives that exhibit higher anti-leukotriene activity.
    The active compounds are effective in a wide range of dosages, for example, daily doses may be in the range of 0.5-300 mg / kg, more using the 1st interval of 100 mg / k4, the amount administered should be determined by a physician depending on circumstances including conditions. treatment, the choice of compound to be administered, and the choice of method of administration of the drug, and, therefore, the dosage limits are not limited by the invention.
    Example 1, 1- 2-Oxy-3-propyl-4- (4-bromomethylphenylmethoxy) phenyl ethanone,
    To a solution of 1- (2,4-dioxy-3-propylphenyl) ethanone (10.0 g, 0.051 mol in dry methyl ethyl ketone (100 ml) was added dried anhydrous sodium carbonate (27 g, 5 mol-eq.) And iodide Sodium (0.5 g) is added to the stirred suspension in 6, cc -dibromo-p-xylene (13.5 g, 0.051 mol), after which the suspension is gently heated under reflux for five hours. The cooled suspension is evaporated in vacuum under reduced pressure, the residue is dissolved in water and extracted twice with dichloromethane. The organic extract is washed with an aqueous solution of sodium hydroxide ( 2N), then with water, dried
    over magnesium sulphate, filter off 4-(4-cyanomethylphenylmethoxy) filter and evaporate to dryness under reduced pressure, thus obtaining a yellow solid residue. The residue is stirred with ether (200 ml) in
    Neil Ethanon
    1 -2-Oxy-3-propyl-4- (4-bromomethyl phenylmethoxy) phenyl ethanone (7.2 g, 0.02 mol) and potassium hydroxide (2.5 g
    one hour and filtered to remove any unreacted impurities. The evaporated filtrate
    under reduced pressure, leaving a yellow solid residue. The solid residue is chromatographed on a column and 30 from Sorbsil using dichloromethane, after which a white solid is obtained, it is recrystallized from methanol, t, mp, 98-99 ° C,
    Example 2. 1-2-hydroxy-3-propyl-4-4- (2-bromoethyl) phenylmethoxy phenyl ethanol,
    To a solution of 1- (2,4-dioxy-3-propylphenyl) ethanone (10.0 g. O, 051 mol) in dry methyltstilketone (100 ml) is added dried anhydrous sodium carbonate (27 g, 5, mol). eq) and io
    sodium chloride (0.5 g); 4- (2-bromoethyl) phenylmethyl bromide (14.2 g. O, 051 mol) is added to the stirred suspension and the suspension is gently heated with
    reflux overnight. The cooled suspension is evaporated under reduced pressure, the residue is taken up in water and extracted with two portions of dichloromethane. Organic
    the extract is washed with an aqueous solution of sodium hydroxide (2N), then with water, dried over magnesium sulphate, filtered and evaporated under reduced pressure to obtain a yellow oil. The oil is chromatographed on a column and 30 with Sorbsil using dichloromethane as eluent and a pale yellow oil is obtained, which crystallizes on standing, forming white crystals, is recrystallized from ethyl alcohol, m, pl. 66-70 s,
    Examples 3-5, Similarly, were obtained: - 2-hydroxy-3- -propyl-4 (2-bromomethylphenylmethoxy) - phenyl ethanone, t, mp, 137-139 ° C;
    1- 2-hydroxy-3-propyl-4 (3-bromomethylphenylmethoxy) phenyl ethanone, t, mp, 135-136 ° C;
    1- 2-hydroxy-3-propyl-4- 4- (3-bromopropyl) phenylmethoxy phenyl ethanone, t, mp, 66-68 ° C,
    Example 6, 1- 2-Oxy-3-pro
    drank-4- (4-cyanomethylphenylmethoxy) phenyl ethanone,
    1 -2-Oxy-3-propyl-4- (4-bromomethylphenylmethoxy) phenyl ethanone (7.2 g, 0.02 mol) and potassium hydroxide (2.5 g.
    0.04 mol) is dissolved in dry dimethyl sulfoxide (60 ml) and stirred at room temperature for two hours. The solution is poured into water with stirring and filtered to obtain a creamy solid residue, which is dried at 60 ° C under reduced pressure. Then recrystallized from ethanol and get a solid pale cream color, so pl, TK-Ub With
    Examples 7-10. Similarly, receive:
    1 - 2-hydroxy-3-propyl-4- (3-cyanomethylphenylmethoxy) phenyl 2 ethanone, t, mp,
    1 -2-hydroxy-3-propyl-4- (2-cyanophenylmethoxy) phenyl / ethanone, m.p. I 57-1 59
    1- 2-hydroxy-3-propyl-4- (2-cyano-ethyl) phenyl methanoxy phenyl ethanone, t, mp 120-123 ° C;
    1- 2-hydroxy-3-propyl-4-4- (3-cyanopropyl) phenylmethoxy | phenyl ethanone, mp, 37-38 ° С,
    Example 1.1, 1- 2-Oxy-3-propyl-4- (4-thiocyanomethylphenylmethoxy) - phenyl ethanone,
    1 -2-Oxy-3-propyl-4- (4-bromomethyl phenylmethoxy) phenyl ethanone (6.4 g, 0.034 mol) and potassium thiocyanate (3.3 g 0.034 mol) are dissolved in dry dimethyl sulphoxide (60 ml ) and stirred at room temperature for four hours. Then the solution is poured into water, stirred and filtered to obtain a white solid, which is dried under reduced pressure at. After recrystallization from ethanol, white crystals are obtained, m, 110-11 1 C,
    Examples 12-15, Similarly receive;
    1- 2-hydroxy-3-propyl-4- (3-thiocyanomethylphenylmethoxy) phenyl ethane, t, mp, 87-88 ° C (CjHjOH);
    1 -2-hydroxy-3-propyl-4- (2-thiocyanomethylphenylmethoxy phenyl) ethanone, t, mp, 118-120 ° C (CjHjOH);
    1- 2-hydroxy-3-prop-1-4-4- (2-thiocyanethyl) -phenylmethoxy3 phenyl ethanone, t, pl. 87-89 with ();
    1- 2-OXY-3-PROPIL-4- 4- (3-thiocyanapropyl) phenylmethoxyphenyl ethanol, t, pl. 53-55 ° C (CjHyOH),
    EXAMPLE 16, 1-2-hydroxy-3-propyl-4-4- (1H-tetrazole-5-sh1methyl) phenyl methoxy phenyl ethanone.
    40585-
    1 -2-Oxy-3-propyl-4- (4-cyano-methylphenylmethoxy) phenyl | ethanone (4.25 g, 0.013 mol) is dissolved in dry dimethylformamide (70 ml), to which sodium azide (3.42 g, 0.052 mol) and ammonium chloride (1.4 g 0.026 mol) are added. The resulting suspension is heated for 20 hours while stirring under a capillary-air cooler. The cooled mixture is poured into water with stirring, acidified and filtered to obtain a pale brown solid.
    15 colors. The solid is transferred into an aqueous solution of sodium hydroxide, washed with chloroform and acidified with concentrated hydrochloric acid under cooling and stirring, after filtration a solid brown-colored solid is obtained, recrystallized from methanol to give a yellowish-brown solid, t , pl, 18425
    crystalline 187 ° C
    17-20, similar
    Examples of the way get
    1-G2-hydroxy-3-propyl-4- 1,2- (1H-tetrazol-5-ylmethyl) phenylmethoxy} phenyl: 0 ethanone, t, mp, 202-204 ° C (MeOH);
    1- 2-hydroxy-3-propyl-4- 3- (1H-tetrazol-5-ylmethyl) phenylmethoxy phenyl ethanone, t, mp, 170-173 ° C (MeOH);
    1- 2-hydroxy-3-propyl-4- (1H-: tetrazol-5-yl) ethyl phenylmethoxyphenyl ethanone, t, mp, 202-204 s (MeOH);
    1- 2-hydroxy-3-propyl-4 - ((B-tetrazol-5-yl) propyl phenyl metalloxyphenyl ztanone, t, mp, 1-163-138 ° С (MeOH) ,,
    0
    Example 21, 1- {2-Hydroxy-3-propyl-4-4- (1H-tetrazol-5-ylthiomethyl) - phenylmethoxy phenyl | ethanone,
    1 -2-Oxy-3-propyl-4- (4-thiocino5 tylphenylmethoxy) phenyl ethanone (6.0 g, 0.017 mol) was dissolved in a mixture of dioxane-water (80-20, 120 ml) to which was added azide sodium (4.4 g, 0.068 mol) and ammonium chloride (1.8 g, 0.034 mol),
    0 The resulting solution was heated at 89 ° C for 18 hours, cooled and poured into water. The resulting solution was acidified with concentrated hydrochloric acid, from (1 watered and rinsed with water, leaving a white solid on the filter. Recrystallized from methanol to obtain a cream-colored crystalline substance, mp, 160-161 ° С,
    Examples 22-25. Similarly, Gülucheny:
    1- 2-hydroxy-3-propyl-4- 2- (1H tetrazol-5-ylthiomethyl) phenylmethoxySphenyl - etalon, t. Pl. 174-176 s (MeOH);
    1- 2-hydroxy-3-proLyl-4-C3 (1H-tetrazole-5-thioylmethyl) phenylmethoxy phenyl ethanone, m.p. 146-148 s (MeOH);
    1- 2-hydroxy-3-propyl-4-4- 2- (1H-tetrazol 5-ylthio) ethyl phenylmethoxyphenyl ethanone; mp. 165-168 ° C (MeOH);
    - 2-hydroxy-3-propyl-4-4-f3- (1H-tetrazol-5-ylthio) propyl phenylmethoxyphenyl ethanone, m.p. 119-121 ° C (MeOH).
    The possibility of using the obtained compounds as leukotriene antagonists is shown on the Gunea Pig test of the in vivo pulmonary function of the guinea pigs at an intravenous dose of 0.05-5 mg / kg or on a modified Hevzheimer test at doses of 25-200 mg / kg. The test is based on allergic bronchospasm.
    In the Hevzheimer test, animals are pretreated with a histamine antagonist-mepyramine, the dose used is 0.5 mg / kg at the initial time 30 minutes before the attack with the antigen. This modification hides the action of histamine, better revealing the result of the action of leukotrienes.
    Tests show that 1C against LTD for the known 4- (3-4-acetyl-3-hydroxy-3-methyl-HOKCHj propoxybenzoic acid) compound is 18 µmol, for the proposed compound (Examples 20,23,24 and 25) ICgQ respectively equal to; 0.095 0.25 0.12, 0.35 (μmol).
    Thus, the compounds obtained have a higher biological activity than the known compounds.
    1340585
    Formulas
    the invention
    The method of producing tetrazole derivatives of the general formula
    VO-CH -f VR5-Sp
    NTCHh .. to
    , t
    where K, -Kz - hydrogen; C, -C-alkyl;
    R4. — CO, where —C — C — alkyl;
     - C, -C-alkyl;
    ,one,
    characterized in that the compounds of the formula
    HE,
    Where
    R, -Rj are as defined,
    subjected to interaction with the compound of the General formula
    Br- (
    where RI has the indicated value, in the anhydrous lower ketone in the presence of alkali metal carbonate, the resulting product is reacted with alkali metal cyanide and at room temperature in anhydrous dimethyl sulfoxide, the resulting product is treated with an alkali metal in the presence of aluminum chloride at 89 -110 ° C in an aprotic solvent medium.
    Compiled by M. Merkulov. Editor V. Danko Tehred I.Popovich Proofreader E.Roshko
    Order 4355/58 Circulation 371Subscription
    VNIIPI USSR State Committee
    for inventions and discoveries 113035, Moscow, Zh-35, Raushsk nab., 4/5
    Production and printing company, Uzhgorod, st. Project, 4
    权利要求:
    Claims (1)
    [1]
    Claim
    A method of obtaining derivatives of tetrazole of the General formula where R t -R 3 is hydrogen; C 4 -C 4 alkyl;
    R 4 is CO, where R 4 ~ C 1 -C 4 is alkyl;
    R ^ is C 1 -C 4 alkyl;
    P = 0.1, characterized in that the compounds of the formula are mepiramine antagonist, the dose used is 0.5 mg / kg at the initial moment 30 minutes before the antigen attack. This modification hides the action of histamine, better revealing the result of the action of leukotrienes.
    Tests show that 1C 0 against LTD 4 for the known compound 4- (3— [4-acetyl-3-hydroxy-3-methylphenoxy] propoxybenzoic acid is 18 μmol for the proposed compound (examples 20,23,24 and 25) 1С 50 is respectively equal; 0.09, 0.25, 0.12, 0.35 (μmol).
    Thus, the obtained compounds have a higher biological activity compared to those known where Rj-Rj have the indicated meanings, are reacted with a compound of the general formula
    Br-CH ^ - ♦ where IC has the indicated meaning in anhydrous lower ketone in the presence of an alkali metal carbonate, the resulting product is reacted with an alkali metal cyanide at room temperature in anhydrous dimethyl sulfoxide, the resulting product is treated with an alkali metal azide in the presence of aluminum chloride at 89-110 C in an environment with compounds, an aprotic solvent.
    类似技术:
    公开号 | 公开日 | 专利标题
    RU2096411C1|1997-11-20|Derivatives of benzimidazolone, mixture of their isomers or their acid additive salts as antagonist of receptor 5htia and 5ht2
    RU1836344C|1993-08-23|Method for obtaining pteridine-4| or their pharmaceutically acceptable salts with alkali metals
    US3282938A|1966-11-01|3-tertiary aminoloweralkyl-4-lower alkyl or phenyl-7-lower carbalkoxy lower alkyl or carboxy lower alkyl coumarins
    SU929009A3|1982-05-15|Process for producing benzofuranyl-benzimidazoles
    SU508205A3|1976-03-25|The method of obtaining derivatives of isoflavone
    SU1340585A3|1987-09-23|Method of producing derivatives of tetrazole
    LU84562A1|1983-09-08|2- | BUTYL) -1-PIPERAZINYL) PYRIDINES
    FI63573C|1985-05-15|FREEZING FOR OXIBENSOTIAZINE DIOXIDERS CABOXAMIDERS
    US4325964A|1982-04-20|Phenylamidine derivatives
    JP2765876B2|1998-06-18|Pyridyl ketoxime ether derivatives
    AU752993B2|2002-10-03|Antidiabetic piperazine derivatives, processes for their preparation and compositions containing them
    SU428602A3|1974-05-15|METHOD OF OBTAINING BASIC-SUBSTITUTE DERIVATIVES 1
    US2587262A|1952-02-26|Chs chzghjoh
    US3891641A|1975-06-24|3-Aminoalcoxy-6-hydrazino pyridazines
    US4140858A|1979-02-20|3-|-2-|indoles and a method for their production
    US5198441A|1993-03-30|Derivatives of 1,2-dihydro 2-oxo quinoxalines, their preparation and their use in therapy
    US2535971A|1950-12-26|1-carbalkoxy-4-substituted piperazines
    US4806660A|1989-02-21|Aurone oxypropanolamines
    US3637853A|1972-01-25|O o'-bis|-diisoeugenol and salts thereof
    PL133507B1|1985-06-29|Method of obtaining cymethydine
    FI78291C|1989-07-10|FOR EXAMINATION OF THERAPEUTIC FRAME THERAPEUTIC 1-PHENOXY-3-HYDROXY-INDOLYL-ALKYLAMINO-3-PROPANOLER.
    JP4452969B2|2010-04-21|Indole compound, its production method and use
    CS196302B2|1980-03-31|Process for preparing new substituted arylalkylamines
    US4031094A|1977-06-21|N-meta-trifluoromethylpiperazines
    JP2515122B2|1996-07-10|Method for producing anthranilic acid ester
    同族专利:
    公开号 | 公开日
    HU192056B|1987-05-28|
    ES534269A0|1985-09-16|
    GB8417753D0|1984-08-15|
    HUT37920A|1986-03-28|
    FI842724A0|1984-07-06|
    GB8318889D0|1983-08-17|
    IL72363A|1987-12-31|
    PT78870A|1984-08-01|
    FI842724A|1985-01-14|
    AU3052684A|1985-01-17|
    EP0132124A1|1985-01-23|
    PL143372B1|1988-02-29|
    US4675334A|1987-06-23|
    AR242197A1|1993-03-31|
    GR81519B|1984-12-11|
    AT29878T|1987-10-15|
    KR850001177A|1985-03-16|
    PH20771A|1987-04-10|
    GB2143817B|1987-04-23|
    EP0132124B1|1987-09-23|
    DE3466389D1|1987-10-29|
    DK343684A|1985-01-14|
    ZA845299B|1985-02-27|
    PL248668A1|1985-07-30|
    GB2143817A|1985-02-20|
    DK343684D0|1984-07-12|
    NZ208837A|1987-07-31|
    PT78870B|1986-10-23|
    IL72363D0|1984-11-30|
    JPS6038351A|1985-02-27|
    CA1222517A|1987-06-02|
    ES8507450A1|1985-09-16|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    BE642636A|1968-01-19|
    US3972934A|1969-05-28|1976-08-03|Eli Lilly And Company|3-Substituted phenylalkyl amines|
    GB1377179A|1970-12-17|1974-12-11|Polaroid Corp|Hydrolysable photographic compounds and products containing them|
    DE2950608C2|1978-12-29|1990-09-13|Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt., Budapest, Hu|
    GB2041363B|1979-01-19|1982-10-06|Pfizer Ltd|N-benzyl-imidazoles|
    NZ194844A|1979-09-05|1983-07-29|Glaxo Group Ltd|Phenoxyalkoxyphenyl derivatives and pharmaceutical compositions|
    FI73423C|1980-02-29|1987-10-09|Otsuka Pharma Co Ltd|FRAMEWORK FOR THE FRAMEWORK OF PHARMACOLOGICAL VEHICLES TETRAZOLDERIVAT.|
    GR76950B|1980-12-18|1984-09-04|Wellcome Found|
    EP0056172B1|1981-01-09|1985-04-03|FISONS plc|Phenoxy- and thiophenoxy compounds, methods for their preparation and pharmaceutical formulations containing them|US4973731A|1987-04-23|1990-11-27|Riker Laboratories, Inc.|Di-t-butylphenyl alkyl and benzyl ether nitriles|
    US4968710A|1987-11-13|1990-11-06|Riker Laboratories, Inc.|Substituted di-t-butylphenols and anti-allergic use thereof|
    US5066822A|1987-11-13|1991-11-19|Riker Laboratories, Inc|Di-t-butylphenols substituted by an alkoxy or benzyloxy group or a benzylthio group|
    US5527945A|1989-02-10|1996-06-18|Basf Aktiengesellschaft|Diphenylheteroalkyl derivatives, the preparation thereof and drugs and cosmetics prepared therefrom|
    EP0741125A1|1992-11-02|1996-11-06|Shionogi Seiyaku Kabushiki Kaisha|Benzyl compounds and process for producing same|
    CA2102078A1|1992-11-02|1994-05-03|Akira Takase|A process for producing -alkoxyimino or hydroxyiminoacetamide compounds and intermediates therefor|
    US5629442A|1993-07-02|1997-05-13|Shionogi & Co., Ltd.|Process for producing α-hydroxyiminophenylacetonitriles|
    JP2006502143A|2002-08-26|2006-01-19|メルク　エンド　カムパニー　インコーポレーテッド|An acetophenone potentiator of metabotropic glutamate receptors|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    GB838318889A|GB8318889D0|1983-07-13|1983-07-13|Pharmaceutical compounds|
    [返回顶部]